Generic placeholder image

Drug Design Reviews - Online (Discontinued)

Editor-in-Chief

ISSN (Print): 1567-2697
ISSN (Online): 1567-2697

Metal-Protein Attenuating Compounds (MPACs) for the Treatment of Alzheimers Disease

Author(s): Kevin J. Barnham, Robert A. Cherny, Roberto Cappai, Simon Melov, Colin L. Masters and Ashley I. Bush

Volume 1, Issue 1, 2004

Page: [75 - 82] Pages: 8

DOI: 10.2174/1567269043480690

Abstract

Aberrant metal protein interactions leading to the generation of toxic reactive oxygen species and protein denaturation have been implicated in a number of neurodegenerative diseases. A breakdown in metal homeostasis plays a critical role in these disorders including Alzheimers disease (AD), where abnormal interactions of copper and zinc ions with ß-amyloid (Aß) may underlie the pathogenesis. We have developed metal-protein attenuating compounds (MPACs) as a novel class of therapeutic agent that target pathogenic interactions of metals with proteins. The prototype for this class of compound is clioquinol (CQ), a small hydrophobic molecule capable of crossing the blood brain barrier. This compound has been shown to have beneficial effects in both a transgenic mouse model of AD and a recently completed small-scale phase II clinical trial.


© 2024 Bentham Science Publishers | Privacy Policy